Citius Pharmaceuticals (NASDAQ:CTXR) Trading 7.1% Higher – What’s Next?

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) traded up 7.1% during trading on Monday . The company traded as high as $0.59 and last traded at $0.5786. Approximately 235,344 shares traded hands during mid-day trading, a decline of 11% from the average daily volume of 265,774 shares. The stock had previously closed at $0.54.

Wall Street Analysts Forecast Growth

CTXR has been the topic of several recent research reports. Zacks Research raised shares of Citius Pharmaceuticals to a “hold” rating in a research report on Tuesday, May 19th. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Citius Pharmaceuticals in a research report on Monday, May 18th. Wall Street Zen cut Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, June 24th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $6.00 target price on shares of Citius Pharmaceuticals in a research note on Wednesday, March 11th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $5.00.

Citius Pharmaceuticals Stock Performance

The stock’s fifty day moving average is $0.64 and its two-hundred day moving average is $0.77. The firm has a market capitalization of $15.88 million, a price-to-earnings ratio of -0.27 and a beta of 1.03.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.67). Sell-side analysts anticipate that Citius Pharmaceuticals, Inc. will post -1.87 earnings per share for the current year.

Institutional Trading of Citius Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd lifted its stake in shares of Citius Pharmaceuticals by 572.8% in the fourth quarter. XTX Topco Ltd now owns 107,118 shares of the company’s stock worth $83,000 after acquiring an additional 91,196 shares in the last quarter. Heights Capital Management Inc. acquired a new stake in Citius Pharmaceuticals during the 4th quarter valued at approximately $622,000. Asset Advisory Group Inc. acquired a new stake in Citius Pharmaceuticals during the 4th quarter valued at approximately $46,000. Finally, NewEdge Advisors LLC purchased a new stake in Citius Pharmaceuticals during the 2nd quarter worth approximately $40,000. 16.88% of the stock is owned by hedge funds and other institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical?stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital?acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter?related bloodstream infections without catheter removal.